| E2696 {hdbayes} | R Documentation |
ECOG E2696 Trial
Description
A data set from the ECOG E2696 trial comparing the combination of the GM2-KLH/QS-21 (GMK) vaccine and high-dose interferon alfa-2b (IFN) therapy with the GMK vaccine alone in resected high-risk melanoma patients. The study results were described in Kirkwood et al. (2001) doi:10.1200/JCO.2001.19.5.1430. This data set only includes patients without nodal metastasis.
Usage
E2696
Format
A data frame with 105 rows and 6 variables:
- failtime
relapse-free survival (RFS) times (in months)
- failind
relapse indicator, 0 = right censored, 1 = relapse
- treatment
treatment indicator, 0 = GMK, 1 = GMK and IFN
- sex
gender indicator, 0 = male, 1 = female
- age
patient age in years
- perform
ECOG performance status indicator, 0 = fully active patient, able to carry on all pre-disease performance without restriction, 1 = restricted in physically strenuous activity, but are ambulatory and able to carry out work of a light or sedentary nature
References
Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., and Chapman, P. B. (2001). High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase II trial E2696. Journal of Clinical Oncology, 19(5), 1430–1436.